Serum metabolites in non-alcoholic fatty-liver disease development or reversion; a targeted metabolomic approach within the PREDIMED trial

Abstract

Background Limited prospective studies have examined changes in non-alcoholic fatty-liver disease (NAFLD) related serum-metabolites and none the effects of NAFLD-reversion. We aimed to evaluate whether perturbations in metabolites indicate predisposition to NAFLD development and to assess the effects of NAFLD reversion on metabolite profiles.MethodsA targeted liquid-chromatography tandem mass-spectrometry metabolic profiling (n = 453 metabolites) approach was applied, using serum from 45 subjects of the PREDIMED study, at baseline and after a median 3.8-year follow-up. NAFLD was determined using the hepatic steatosis index; with three groups classified and studied: Group 1, not characterized as NAFLD cases during the follow-up (n = 15); Group 2, characterized as NAFLD during the follow-up (n = 15); Group 3, characterized as NAFLD-reversion during the follow-up (n = 15).ResultsAt baseline, significantly lower storage and transport lipids (triacylglycerols and cholesteryl esters), several monoetherglycerophosphocholines, acylglycerophosphocholines, ceramides and ceramide to sphingomyelin ratio (P < 0.05), were found; whereas a higher L-cystine to L-glutamate ratio (P < 0.05) was observed, in group 2 as compared to group 1.P-ether acylglycerophosphocholines, ceramides and sphingolipids were significantly different betweengroup 3 and group 1 (P < 0.05). Higher 16:1n-7 to 16:0, and 18:0 to16:0 ratio (P < 0.05), while lower 18:1n-9 to 18:0, 16:0 to 18:2n-6, and 18:3n-6 to 18:2n-6 ratio (P < 0.05) were observed in the final, compared to baseline values, in groups 2 and 3.ConclusionThe rearrangement of lipid biosynthesis and serum transport may indicate predisposition to NAFLD development. Despite an expected reduction of hepatic lipotoxicity and improved hepatic function in the participants of the study characterized as NAFLD-reversing, the side effects of NAFLD in serum metabolic profiles remained present.Trial registrationThe trial is registered at ISRCTN35739639. Registration date: 5th October 2005.Electronic supplementary materialThe online version of this article (doi:10.1186/s12986-017-0213-3) contains supplementary material, which is available to authorized users.

Phospholipid Remodeling in Physiology and Disease

“…Recent studies demonstrated that LPCATs may also contribute to the pathogenesis of NAFLD. Attempts to identify diagnostic markers of NAFLD have found that serum lysoPC levels are decreased in NASH patients (116)(117)(118). Similar decreases in serum lysoPC levels were observed in a mouse NASH model induced by a methionine-and choline-deficient (MCD) diet (119).…”

Metabolomic and Lipidomic Biomarkers for Premalignant Liver Disease Diagnosis and Therapy

“…(all in serum) [241] [228] [240] Overall Summary A summary of metabolic, metabolomic, and lipidomic investigations into ALD is given in Table 1. It is clear that the hepatic metabolic phenotypes and therefore biomarkers of both chronic alcohol consumption and ALD are far from being defined.…”

Study of the Serum Metabolomic Profile in Nonalcoholic Fatty Liver Disease: Research and Clinical Perspectives

“…Papandreou et al [ 21 ] analyzed the rearrangement of lipid biosynthesis occurring in patients with non-alcoholic liver steatosis with a follow-up period of 3.8 years. They subdivided 45 patients into the following subgroups: (1) HC; (2) liver steatosis; (3) liver steatosis reversion during the follow-up.…”